drugset / Trial / NCT06534411
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
Timeline
- Start
- 2024-11-05
- Primary completion
- 2026-06-02
- Completion
- 2026-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cagrilintide | Protein / enzyme biologic | 1 mg | Subcutaneous |
| Subject | Semaglutide | Peptide | 1 mg | Subcutaneous |
| Subject | Tirzepatide | Peptide | 5 mg | Subcutaneous |